RecruitingPHASE1, PHASE2NCT06378242

To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2

Studying Muscular tumor

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
RemeGen Co., Ltd.
Intervention
Disitamab Vedotin for injection(drug)
Enrollment
24 enrolled
Eligibility
18-75 years · All sexes
Timeline
20242029

Study locations (6)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06378242 on ClinicalTrials.gov

Other trials for Muscular tumor

Additional recruiting or active studies for the same condition.

See all trials for Muscular tumor

← Back to all trials